The Centers for Medicare and Medicaid Services (CMS) early Tuesday announced the first 10 drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).

These single-source drugs were chosen based on their eligibility under the IRA and are the “highest total Part D gross covered prescription drug costs” under Medicare Part D, according to the CMS. In total, these medications account for $50.5 billion in total gross Part D costs.

Negotiations over these drugs, if manufacturers agree to the process, will take place over 2023 and 2024. Drugmakers have until Oct. 1 to sign agreements.